News

?

?The 105th Annual Meeting of the American Association for Cancer Research will be held April 5–9, 2014, in San Diego, California. The Annual Meeting theme of this year is "Harnessing Breakthroughs / Targeting Cures". About 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world scheduled to be in attendance.

?

?

??

?

?HEC has established competitive pipeline in oncology therapeutic area. CT053, a C-met inhibitor against cancer and CT207 and CT317, the pro-drugs of BRAF inhibitor Vemurafenib, will be disclosed at this meeting. CT053 is a novel c-MET, Axl and VEGFR2 inhibitor that potently suppresses angiogenesis and tumor gowth. CT053 is now in the phase 1 study in China. CT207 and CT317 shows good druggability with much improved oral bioavailability for original drug. Both of them have been applied for patents. To date, no competitor products have registered and launched in China

??

?In the annual meeting, HEC chief scientist of Oncology, Dr. Ning Xi will make a presentation focusing on the HEC candidate drugs above. To attend the meeting will deeply connect HEC with industry and academic that will promote and re-position the oncology research strategy of HEC.

??

?Presentation Topics:

??

?(1) 3PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth

??

?(2) Vemurafenib prodrugs suitable for oral and IV administration

??

?Session Time:   Monday, April 7, 2014, 8:00 – 12:00

??

?Session ID:     Experimental and Molecular Therapeutics 12

??

?Session Title:  Kinase Inhibitors 2

??

?Location:         Hall A-E, Poster Section 31

??

?Poster Board Number:    28 

?